  |
|
 |
|
Case Report
| ||||||
| Vancomycin-associated neutropenia in hemodialysis patient with sepsis | ||||||
| Esraa Shukri Altawil1, Fadi Saleh Aljamaan2 | ||||||
|
1Critical Care Clinical Pharmacist, Pharmacy department, KSUMC, Riyadh, SA.
2MD, Assistant Professor, Intensive Care Department, KSUMC, Riyadh, SA. | ||||||
| ||||||
|
[HTML Full Text]
[PDF Full Text]
[Print This Article]
[Similar article in Pumed] [Similar article in Google Scholar] 
|
| How to cite this article |
| Altawil ES, Aljamaan FS. Vancomycin-associated neutropenia in hemodialysis patient with sepsis. Int J Case Rep Images 2017;8(3):184–186. |
|
Abstract
|
|
Introduction:
Vancomycin-induced neutropenia is a rare but serious adverse reaction that appears to occur with prolonged use with a minimum of seven days. In most cases, it has been reported to resolve spontaneously upon discontinuation of vancomycin.
Case Report: A 53-year-old male admitted as a case of septic arthritis complicated with sepsis in which vancomycin induced prolonged neutropenia occurred after nine days of therapy and was associated with toxic serum level. Conclusion: Vancomycin induced neutropenia may occur at any dose or duration of therapy, but generally it is associated with prolonged use for more than seven days. Our findings suggest that clinicians should be cautious about it as it can occur at any time in the course of treatment, and may last for longer time especially in hemodialysis patients in addition to being linked to the toxic serum level. All patients who receive vancomycin for more than seven days should have white blood cells count and differential counts monitored weekly. Discontinuation of the drug appears to be prudent as soon as this hematological abnormality detected. | |
|
Keywords:
Vancomycin, Neutropenia, Sepsis, Toxic level
| |
|
[HTML Full Text]
[PDF Full Text]
|
|
Author Contributions
Esraa S. Altawil – Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published Fadi S. Aljamaan – Analysis and interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published |
|
Guarantor of submission
The corresponding author is the guarantor of submission. |
|
Source of support
None |
|
Conflict of interest
Authors declare no conflict of interest. |
|
Copyright
© 2017 Esraa S. Altawil et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information. |
|
|